NCT02085252View on ClinicalTrials.gov

A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

June 3, 2013

Primary Completion Date

November 8, 2016

Study Completion Date

November 8, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Leuprorelin

Solution for injection

DRUG

Bicalutamide

Bicalutamide tablets

Trial Locations (2)

75020

Tenon Hospital Paris France, Paris

92977

Ouzid, Paris La Défense,, Paris

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY